VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
The live audio webcast will be available online, with telephone dial-ins for U.S./Canada, U.K., and international participants and a replay accessible until April 15, 2026 (Conference ID 13759627).
Senior management and scientific officers will present and take questions about 2025 events, subsequent developments, and upcoming milestones.
Positive
- None.
Negative
- None.
News Market Reaction – VNRX
In the Mar 26 session, VNRX gained 0.89%, reflecting a mild positive market reaction. Argus tracked a peak move of +32.7% during that session. Argus tracked a trough of -15.9% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 6.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-11-10 | Q3 2025 call scheduled | Neutral | +0.6% | Announced Q3 2025 earnings and business update conference call logistics. |
| 2025-08-08 | Q2 2025 call scheduled | Neutral | +0.5% | Scheduled Q2 2025 earnings call with access details and replay info. |
| 2025-05-12 | Q1 2025 call scheduled | Neutral | -1.0% | Set date and dial-in details for Q1 2025 earnings and business update. |
| 2025-03-25 | FY 2024 call scheduled | Neutral | +0.9% | Announced timing and access for full-year 2024 earnings conference call. |
| 2024-11-08 | Q3 2024 call scheduled | Neutral | +5.4% | Planned Q3 2024 earnings call and business update with replay details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings and business update calls has historically coincided with modest, mostly low-single-digit stock moves for VNRX.
Over the past year, VolitionRx has regularly issued press releases to schedule quarterly and full-year earnings and business update conference calls. These events, hosted by the core executive team, provided financial results and milestone updates for Q1–Q3 2025 and full-year 2024. Price reactions to these scheduling announcements ranged from small declines to gains up to the mid-single digits, with an average move near 1.26%. Today’s full fiscal year 2025 call scheduling continues this established communication pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to take place on Wednesday, April 1 at 8:30 a.m.
Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call
Date: Wednesday, April 1, 2026
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13759627
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-fiscal-year-2025-earnings-conference-call-and-business-update-302725247.html
SOURCE VolitionRx Limited